AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Continous Positive Airway Pressure (CPAP) Support for Acute Hypoxemic Respiratory Failure in Burkina Faso

RecruitingNAAges 18 Years - anyAllUniversité NAZI BONI
💬

In plain words

What the trial is, and whether it could suit you

Acute respiratory failure (ARF) is a frequent medical emergency, involving high costs for health organizations and patients who often require intensive care and respiratory assistance. According to an international study, 61% of hypoxemic patients in intensive care receive invasive ventilation \[3\]. Invasive mechanical ventilation is often unavailable in low-income countries and non-invasive ventilatory supports such as continuous positive airway pressure (CPAP) and high-flow oxygen therapy (HFO) were very useful during the COVID-19 pandemic. They reduced the rate of intubation and ICU admissions. In addition, CPAP can be used without a ventilator, no electricity is required. So, it could be a support of choice in low-income countries. Used of Boussignac-type CPAP could potentially reduce the recourse to intubation in patients with acute hypoxemic respiratory failure in a context where

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: All patients aged 18 years and older will be included in the study if they meet at least one of the following criteria : * Acute respiratory distress, defined as dyspnea respiratory rate ≥ 25 cycles/min * Hypoxemia, defined as the need for more 6 liters of oxygen to maintain an oxygen saturation (SpO2) of ≥ 92%. The fraction of inspired oxygen (FiO2) will be estimated using the 3% rule. Exclusion Criteria: Patients with any of the following criteria will not be included in the study: * Pregnant or breastfeeding women * Persons deprived of their liberty * Exacerbation of asthma, chronic obstructive pulmonary disease, or another chronic respiratory disease * Moderate to large amount of unilateral or bilateral undrained pleural effusion * Contraindication to CPAP: patient refusal, undrained pneumothorax, chest injury, repeated or large vomiting, upper gastrointestinal bleeding, craniofacial trauma, severe upper airway obstruction, or tetraplegia in the initial phase * Cardiac arrest, severe arrhythmias, shock requiring the use of vasopressors (norepinephrine, adrenaline, dopamine) * Altered level of consciousness (Glasgow Coma Scale score \< 13), repeated seizures, or status epilepticus * Medical decision to limit treatment: no intubation, no admission to intensive care * Refusal to participate in the study or participation in another interventional study on respiratory distress or acute respiratory failure.
💊

What it tests

  • CPAP
📍

Where

4 sites
Centre Hospitalier Universitaire Souro Sanou
Bobo-Dioulasso, Burkina Faso
CHU Yalgado Ouedraogo
Ouagadougou, Burkina Faso
CHU Tengandogo
Ouagadougou, Burkina Faso
CHU Bogodogo
Ouagadougou, Burkina Faso
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy